Brief Communication COVID-19 in the Midst of Malaria, Cold, and Flu in Nigeria |
Uchejeso Obeta1*, Gumta Matthew2, Obiora Ejinaka3 |
|
1Department of Medical Laboratory Management, Federal School of Medical Laboratory Science, Jos-Nigeria. 2Department of Family Medicine, Our Lady of Apostle Hospital, Jos-Nigeria. 3Department of Medical Parasitology, Federal School of Medical Laboratory Science, Jos-Nigeria. |
ABSTRACT
There is a relationship existing in the nature of management of COVID-19, malaria, cold, and flu ranging from the use of anti-malaria to immune boosters such as vitamin C, herbal/home remedies, large intake of fluids and rest while recommending conventional drugs. This study was done to establish the relationships in terms of clinical symptoms, diagnosis and management. In Nigeria, NAFDAC acknowledged the positive effects of vitamin C enriched plants and vegetables on COVID-19 as discovered by researchers and academicians but discouraged the use of any local products without adequate registration before making claims and usage. There is enormous fear because of the delta variant of COVID-19 because of little or absence of known symptoms, but on the other hand, the majority of affected cases of COVID-19 in Nigeria were asymptomatic and this calls for serious concern in the presence of malaria, cold and flu and that is why the comparison is germane to assist management. The positive relationship would assist in the multiple approach in handlind COVID-19, malaria, cold and flu especially in Nigeria.
Key Words: COVID-19, Malaria, Cold, Flu, Comparison
INTRODUCTION
On July 17, 2021; the Nigerian Presidential Steering Committee on COVID-19 issued a press statement on the COVID-19 third wave following the confirmation of the Delta variant in Nigeria. The statement as well puts six states including Lagos, Oyo, Kaduna, Rivers, Kano, and Plateau states and FCT at alert especially during the Eid celebration [1-3]. COVID-19 having arrived in Nigeria on February 27, 2020 (1 year, 4 months, 2 weeks, and 6 days) have affected 169, 206 persons with 2, 126 deaths putting the fatality rate in Nigeria at 1.26% [4].
On the contrary, Malaria has existed for decades with numerous attentions but not as that of COVID-19. In 2018, WHO [5] puts 93% of global cases in Africa with 28% of them coming from Nigeria where 24% of the death cases took place. Nigeria leads in Malaria burden across the globe. Several efforts to tackle the malaria burden have also been hampered by the COVID-19 pandemic [6, 7]. It seems that the similarity of COVID-19 which mostly affects the developed countries is malaria in Africa among the low and medium-income countries (LMICs) especially in Nigeria. COVID-19 has been said to be zoonotic [8] while malaria is parasitic [7] but cold and flu are equally of the viral origin.
MATERIALS AND METHODS
Review on some published works were carried out to assess the relationship especially in the area of similarities towards relating COVID-19, malaria, cold and flu.
RESULTS AND DISCUSSION
From the literatures assessed, there is evidence of clinical features overlap seen in COVID-19, malaria, cold, and flu as shown in Table 1. The result presents among other things, the feautures, symptoms, diagnosis, management using the conventional and complementary medicines with instances of vitamin C enriched plants.
There is an overlapping similar features among COVID-19, malaria, cold, and flu in terms of signs and symptoms, diagnosis, and management not minding some issues associated with causes, and control. The case of COVID-19 has created a challenge for health care workers, community members, patients, and patients’ relatives due to overlapping symptoms and treatment in Nigeria [9-11]. World Health Organization as recorded by Shi et al. [12], gave a marching order for an urgent and aggressive tackling of COVID-19 to ensure that other diseases, like malaria, are not neglected. In aggressive battling of COVID-19 (1.26% fatality) amidst Malaria (20%), Lower Respiratory Infection (19%), HIV/AIDS (9%), Diarrheal Diseases (5%), Road Injuries (5%), Protein Energy Malnutrition (4%), Cancer (3%), Meningitis (3%), Stroke (3%) and Tuberculosis (2%) with cold and flu up to 2% in Nigeria [13], there is urgent need to reassess the health policies and set our priorities as a nation.
The zeal exhibited by government and her agencies towards COVID-19, including the malaria drug administration made Dokpesi [14] to question, “What is the difference between COVID-19 and malaria? When did malaria become synonymous with COVID-19?” These questions were based on the treatment which was mostly antimalarial drugs to him and all around him during COVID-19 treatment. This was further buttressed by the order given by Governor San-nwolu [15] of Lagos state to treat malaria-like symptoms as COVID-19 to flatten the curve as fast as possible. Though controversy exists on Madagascar’s COVID-19 organic as clinical trial results are still awaited, the FMOH-Nigeria [16] in their assessment revealed that the organic is mainly an antimalarial drug.
There is no doubt that a relationship exists (Table 1) like management of COVID-19, malaria, cold, and flu ranging from the use of anti-malaria, to immune boosters such as vitamin C [17], herbal/home remedies [18-20], large intake of fluids and rest while taking recommended conventional drugs. NAFDAC has equally acknowledged the positive effects of vitamin C enriched plants and vegetables on COVID-19 as discovered by researchers and academicians but encouraged them to register such products adequately before making claims [21].
COVID-19, malaria, cold and flu shares a lot of similarieties in clinical signs and sypmtoms, diagnosis, managements and control available. There is enormous fear because of the delta variant of COVID-19 because of little or absence of known symptoms, but on the other hand, the majority of affected cases of COVID-19 in Nigeria were asymptomatic and this calls for serious concern in the presence of malaria, cold and flu.
The authors hereby recommend:
Table 1. Relationship among COVID-19, Malaria, Cold, and Flu
SN |
ISSUES |
COVID-19 |
MALARIA |
COLD |
FLU |
AUTHORS |
SYMPTOMS [9-12] |
||||||
1 |
Acquired time/ incubation period(days) |
2-14 |
7-30 |
1-3 |
1-4 |
|
2 |
Arrival/onset of symptoms |
Gradual |
Gradual |
Gradual |
Abrupt |
|
3 |
Body pains |
Sometimes |
Sometimes |
Slight |
Common |
|
4 |
Chills |
Sometimes |
Most times |
Uncommon |
Very common |
|
5 |
Cough |
Common |
Sometimes |
Not common |
Common |
|
6 |
Diarrhea |
Sometimes |
Not common |
Not common |
Sometimes |
|
7 |
Difficulty in Breathing |
Common |
Mild |
Mild |
Sometimes |
|
8 |
Fatigue |
Common |
Common |
Common |
Sometimes |
|
9 |
Fever |
Common |
Common |
Rare |
Common |
|
10 |
Headache |
Sometimes |
Common |
Rare |
Common |
|
11 |
Loss of Appetite |
Sometimes |
Common |
Sometimes |
Common |
|
12 |
Loss of smell |
Sometimes |
Sometimes |
Sometimes |
Sometimes |
|
13 |
Loss of taste |
Sometimes |
Sometimes |
Rare |
Sometimes |
|
14 |
Nasal congestion |
Sometimes |
Sometimes |
Common |
Sometimes |
|
15 |
Respiratory issues |
Common |
Sometimes |
Sometimes |
Sometimes |
|
16 |
Running nose |
Sometimes |
Sometimes |
Common |
Sometimes |
|
17 |
Sore throat |
Sometimes |
Sometimes |
Common |
Sometimes |
|
CAUSES [11, 12] |
||||||
18 |
Causative Agents |
Virus |
Parasite |
Virus |
Virus |
|
19 |
Agents |
SARS-COV-2 |
Plasmodium spp. |
Rhinovirus Coronavirus RSV Parainfluenza |
Influenza |
|
MEDICAL LABORATORY DIAGNOSIS [22, 23] |
||||||
20 |
Accepted samples |
nasopharyngeal swabs, oropharyngeal swabs, throat swabs, saliva, sputum, bronchoalveolar lavage fluid, blood, stool, urine, |
Blood |
nasopharyngeal swabs, oropharyngeal swabs, throat swabs, sputum, blood. |
nasopharyngeal swabs, oropharyngeal swabs, throat swabs, saliva, sputum, bronchoalveolar lavage fluid, blood. |
|
21 |
Methodology |
virological culture, PCR / gene Xpert, ELISA, biosensors, RDTs |
Microscopy PCR RDTs |
Culture PCR RDTs |
Culture PCR RDTs |
|
22 |
Turnaround time |
2Hours to 3Days |
20Minutes to 24hours |
2Hours to 48Hours |
2Hours to 48Hours |
|
MANAGEMENT [18-20, 24] |
||||||
23 |
Conventional drugs |
Yes including Anti-malaria |
Anti-malaria |
Yes including Anti-malaria |
Yes including Anti-malaria |
|
24 |
Immune boosters |
Yes |
Yes |
Yes |
Yes |
|
25 |
Herbal/home remedies |
Yes |
Yes |
Yes |
Yes |
|
26 |
Rest |
Yes |
Yes |
Yes |
Yes |
|
27 |
Fluid intake |
Yes |
Yes |
Yes |
Yes |
|
VACCINATION [25, 26] |
||||||
28 |
Available |
Yes |
No |
No |
Yes |
|
29 |
Clinical trial |
Yes |
Yes |
No |
Yes |
|
30 |
Immunization ongoing |
Yes |
No |
No |
Yes |
|
SAFETY PROTOCOLS [24] |
||||||
31 |
Enforcement |
Yes |
No |
No |
No |
|
32 |
Hygiene |
Highly done |
Not considered |
Not considered |
Necessary |
|
33 |
Materials |
PPE |
No PPE |
No PPE |
PPE necessary |
|
34 |
Policies |
Very Many |
Many |
None |
Little |
|
PCR- polymerase chain reaction, RDTs- rapid diagnostic techniques, ELISA- Enzyme-linked immunosorbent assay, PPE- Personal protective equipment, RSV- Respiratory syncytial virus, SARS-COV-2- Severe acute respiratory syndrome coronavirus 2
CONCLUSION
There is a relationship existing in the nature of management of COVID-19, malaria, cold, and flu ranging from symptoms, use of anti-malaria, to immune boosters such as vitamin C, herbal/home remedies, and recommended advice to the patients like large intake of fluids, and rest while on treatment. There fear of ravaging variants of COVID-19 could be ameliorated using vitamin C enriched plants and vegetables while adhering to WHO recommended protocols. COVID-19 comparison in the presence of malaria, cold and flu gives germane ideas to assist management.
Acknowledgments: We acknowledge all the researchers of natural products towards curtaling COVID-19 and all agencies involved in treatment / managemnent of COVID-19 in Nigeria.
Conflict of interest: None
Financial support: None
Ethics statement: None
[1] Nigeria Centre for Disease Control - NCDC (2020) Updates on COVID-19 (Coronavirus Disease 2019). Accessed on July 17, 2021, Available from: http://www.covid19.ncdc.gov.ng/
[2] Meconcelli G, Bazzoni G, Casu C. Auriculotherapy for Stress Management as Self-Help in Isolation Situations (COVID 19). Int J Pharm Phytopharmacol Res. 2020;10(3):1-2.
[3] Damanhouri ZA, Alkreathy HM, Ali AS, Karim S. The potential role of Fluoroquinolones in the management of Covid-19 a rapid review. J Adv Pharm Educ Res. 2021;11(1):128-34.
[4] PSCC. Press Statement. Presidential Steering Committee on COVID-19 issued a press statement on the COVID-19 third wave in Nigeria. July 17, 2021.
[5] WHO. The World malaria report 2019 at a glance. 2020. https://www.who.int/news-room/feature-stories/detail/world-malaria-report-2019
[6] Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, et al. The potential public health consequences of COVID-19 on malaria in Africa. Nat Med. 2020;26(9):1411-6. doi:10.1038/s41591-020-1025-y
[7] Hussein MIH, Abdalazim A, Albashir D, Ali O, Elawad MA, Homeida A. Malaria and COVID-19: unmasking their ties. Malar J. 2020;19(1):457. doi:10.1186/s12936-020-03541-w
[8] Etukudoh NS, Ejinaka O, Obeta U, Utibe E, LoteNwaru I, Agbalaka P, et al. Zoonotic and Parasitic Agents in Bioterrorism. J Inf Dis Trav Med. 2020;4(2):000139.
[9] Osman M, Klopfenstein T, Belfeki N, Gendrin V, Zayet S. A comparative systematic review of COVID-19 and Influenza. Viruses. 2021;13(3):452. doi:10.3390/v13030452
[10] Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: a symptom screening challenge for malaria endemic countries. Int J Infect Dis. 2020;94:151-3. doi:10.1016/j.ijid.2020.04.007
[11] Ajayi IO, Ajumobi OO, Falade C. Malaria and COVID-19: commonalities, intersections, and implications for sustaining malaria control. Pan Afr Med J. 2020;37(1):1. doi:10.11604/pamj.supp.2020.37.1.25738. Available from: https://www.panafrican-med-journal.com/content/series/37/1/1/full
[12] Shi B, Zheng J, Xia S, Lin S, Wang X, Liu Y, et al. Accessing the syndemic of COVID-19 and malaria intervention in Africa. Infect Dis Poverty. 2021;10(5). doi:10.1186/s40249-020-00788-y
[13] Muhammad F, Abdulkareem JH, Chowdhury AA. Major public health problems in Nigeria: a review. South East Asia J Public Health. 2017;7(1):6-11. doi:10.3329/seajph.v7i1.34672
[14] Dokpesi A. Coronavirus: I’m Confused, we were given anti-malaria drugs. A daily news post of May 15, 2020. 2020. Available from: https://dailypost.ng/2020/05/15/coronavirus-im-confused-we-were-given-malaria-drugs-dokpesi-video/
[15] Sannwo-Olu B. Lagos to treat malaria-like symptoms as COVID-19 – Governor. Premium times online news of January 19, 2021. 2021. Available from: https://www.premiumtimesng.com/regional/ssouth-west/437455-lagos-to-treat-malaria-like-symptoms-as-covid-19-governor.html
[16] FMOH. Madagascar’s COVID-19 Drug is mainly anti-malaria- Minister of Health. 2020. Available from: https://www.premiumtimesng.com/news/headlines/400785-madagascars-covid-19-drug-is-mainly-anti-malaria-health-minister.html
[17] Ohanube GA, Obeta UM, Ikeagwulonu CR. Case reports in the use of vitamin C based regimen in prophylaxis and management of COVID-19 among Nigerians. J Curr Biomed Rep. 2020;1(2):77-80. www.jcbior.com
[18] Uchejeso OM, Chinaza IR, Goodluck OA, Rinpan JI. Some Igbo Indigenous Plants with Anti-COVID-19 Properties. InAlternative Medicine 2020. IntechOpen. doi:10.5772/intechopen.94244
[19] Ohanube GA, Obeta MU, Ikeagwulonu RC, Jwanse IR. COVID-19: A Case Study of Using Vitamin C Enriched Plants and Ascorbic Acid as Cure. Am J Med Case Rep. 2020;8(11):435-7. doi:10.12691/ajmcr-8-11-16.
[20] Obeta UM, Ohanube GA, Ekpere-Ezeugwu MO, Mantu EC, Etukudoh NS, Akram M, et al. Using decoction of some vitamin C enriched plants for the management of COVID-19 in Jos, Nigeria: A case report. J Curr Biomed Rep. 2021;2(2). www.jcbior.com
[21] NAFDAC. Why we didn’t approve herbal medicine for COVID-19. 2021. Available from: https://www.vanguardngr.com/2021/07/why-we-didnt-approve-herbal-medicine-for-covid-19-treatment-nafdac/
[22] Ikeagwulonu RC, Obeta MU, Ugwu IN. Systematic review of laboratory parameters predicting severity and fatality of COVID-19 hospitalised patients. New Zealand J Med Lab Sci. 2020;74(3):165-80.
[23] Obeta MU, Etukudoh NS, Okoli CC. Nigerian Medical Laboratory Diagnosis of COVID-19; from Grass to Grace as Chapter 5 of Intelligent Computing Applications for COVID-19: Predictions, Diagnosis, and Prevention (Ed.) Saba and Rehman, CRC Press Tailor and Francis Group (Preprint). 2021.
[24] WHO. Clinical management of COVID-19. Interim guidance. 27 May 2020. World Health Organization. 2020. Available from: https://apps.who.int/iris/handle/10665/332196.
[25] WHO. Evaluation of COVID-19 vaccine effectiveness. Interim guidance. 17 March 2021. World Health Organization. 2020. Available from: https://apps.who.int/iris/handle/10665/340301.
[26] Dolgin E. How COVID unlocked the power of RNA vaccines. Nature. 2021;589:190-1.